By a News Reporter-Staff News Editor at Diabetes Week -- Current study results on Nutritional and Metabolic Diseases and Conditions have been published. According to news reporting originating in New Haven, Connecticut, by NewsRx journalists, research stated, "We measured the mRNA and protein expression of the key gluconeogenic enzymes in human liver biopsy specimens and found that only hepatic pyruvate carboxylase protein levels related strongly with glycemia. We assessed the role of pyruvate carboxylase in regulating glucose and lipid metabolism in rats through a loss-of-function approach using a specific antisense oligonucleotide (ASO) to decrease expression predominantly in liver and adipose tissue."
The news reporters obtained a quote from the research from the Yale University School of Medicine, "Pyruvate carboxylase ASO reduced plasma glucose concentrations and the rate of endogenous glucose production in vivo. Interestingly, pyruvate carboxylase ASO also reduced adiposity, plasma lipid concentrations, and hepatic steatosis in high fat-fed rats and improved hepatic insulin sensitivity. Pyruvate carboxylase ASO had similar effects in Zucker Diabetic Fatty rats. Pyruvate carboxylase ASO did not alter de novo fatty acid synthesis, lipolysis, or hepatocyte fatty acid oxidation. In contrast, the lipid phenotype was attributed to a decrease in hepatic and adipose glycerol synthesis, which is important for fatty acid esterification when dietary fat is in excess."
According to the news reporters, the research concluded: "Tissue-specific inhibition of pyruvate carboxylase is a potential therapeutic approach for nonalcoholic fatty liver disease, hepatic insulin resistance, and type 2 diabetes."
For more information on this research see: Targeting pyruvate carboxylase reduces gluconeogenesis and adiposity and improves insulin resistance. Diabetes, 2013;62(7):2183-94. (Elsevier - www.elsevier.com; Diabetes - www.elsevier.com/wps/product/cws_home/707821)
Our news correspondents report that additional information may be obtained by contacting N. Kumashiro, Howard Hughes Medical Institute, Yale University School of Medicine, New Haven, Connecticut, United States. Additional authors for this research include S.A. Beddow, D.F. Vatner, S.K. Majumdar, J.L. Cantley, F. Guebre-Egziabher, I. Fat, B. Guigni, M.J. Jurczak, A.L. Birkenfeld, M. Kahn, B.K. Perler, M.A. Puchowicz, V.P. Manchem, S. Bhanot, C.D. Still, G.S. Gerhard and Pe (see also Nutritional and Metabolic Diseases and Conditions).
Keywords for this news article include: Antisense Technology, Biotechnology, Diabetes, New Haven, Keto Acids, Proinsulin, Connecticut, Therapeutics, United States, Bioengineering, Hyperinsulinism, Peptide Hormones, Insulin Resistance, Pyruvate Carboxylase, Carbon Carbon Ligases, Enzymes and Coenzymes, North and Central America, Glucose Metabolism Disorders.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC